Introduction {#S0001}
============

Colorectal cancer (CRC) is the third most common cancer worldwide.[@CIT0001] The survival outcomes in CRC remain poor, due in part, to the presence of distant metastases.[@CIT0002] Thus, investigating the molecular mechanism of CRC progression and metastasis is crucial in the development of future therapeutic advances. Accumulating evidence has revealed the multistep process in CRC carcinogenesis that involves complicated and dynamic interplay between host genetics, epigenetics and transcriptomic alterations.[@CIT0003],[@CIT0004]

The importance of DNA methylation plays in the proliferation and metastasis of CRC is well-established.[@CIT0005] However, the role of N^6^-methyadenosine (m^6^A) in the modification of RNA remains unclear. m^6^A is recognized as the most common internal modification in mammalian mRNA,[@CIT0006] which is a dynamic reversible process and plays a crucial role in epigenetic regulation.[@CIT0007],[@CIT0008] METTL3 and METTL14 were identified as m^6^A "writers" that form a heterodimeric complex with the support of WTAP in the catalysis of m^6^A methylation.[@CIT0009],[@CIT0010] By contrast, FTO and ALKBH5 are referred to as m^6^A "erasers" that were shown to regulate cancer stem cell properties.[@CIT0011],[@CIT0012] METTL3 was originally identified as a methyltransferase that acted as one component of the methyltransferase complex.[@CIT0013] Furthermore, METTL3 was shown to be essential in cancer cell survival by modifying p53-mediated signaling[@CIT0014] and epigenetically silences tumor-suppressor genes and serves as an oncogene in promoting progression in hepatocellular carcinoma.[@CIT0015] By contrast, METTL3 was reported as a tumor suppressor in kidney cancer.[@CIT0016] Therefore, it is of great significance to explore the functional role and potential mechanism of METTL3 in CRC. Herein, we investigated the function of METTL3 in CRC disease progression. This might reveal the potential for future drug development in the setting of CRC.

Material and methods {#S0002}
====================

CRC specimens and cell-lines {#S0002-S2001}
----------------------------

The samples were collected from patients who underwent surgery at the Taizhou Hospital in Zhejiang province from 2008 to 2011 with a follow-up information till 2017. All clinical samples were collected with written informed consent from patients, and the ethical approval was granted from the Committees for Ethical Review of Shanghai Outdo Biotech Company. The human CRC cell lines (HCT-116, DLD-1, KM-12 and HCT-8) were obtained from the American Type Culture Collection (ATCC) and maintained in RPMI-1640 culture medium that was supplemented with 10% FBSand working strength penicillin-streptomycin Solution as antibiotics (all from Gibco, New York, NY, USA) at 37ºC in an atmosphere of 5% CO~2~ in air. The final concentration of p-38 (SB203580, Selleckchem, Shanghai, People\'s Republic of China) and ERK (SCH772984, MCE) inhibitor was both 2uM.

Establishment of stable knockdown and overexpressed cells {#S0002-S2002}
---------------------------------------------------------

The open-reading frame (ORF) of METTL3 was amplified from the cDNA of HCT-116 cells and inserted into the Psin vector. CRC cells were stably transduced with METTL3-overexpressing lentiviral and Psin control vectors. For the METTL3 knockdown studies, CRC cells were stably transfected with PLKO control vectors and transduced with METTL3 knockdown lentiviral vectors ([Table S1](#ST0001)). Lentiviruses were packaged by transfecting the 3-plasmid transfer vector: psPAX2: pMD2.G=6: 3: 1.5 ug into 293 Ta cells. The released virus in the liquid media was harvested at 48 hrs and 72 hrs post-transduction and concentrated by ultracentrifugation. To establish the stable knockdown and overexpressing cells, both HCT-116 and DLD1 cells were transduced with the lentivirus at a multiplicity of infection (MOI) of 10 with 5 μg/mL polybrene (Sigma, Saint Louis, MO, USA). The stable expressing cells were selected by treating with puromycin for 2 weeks.

Immunohistochemistry and western blotting {#S0002-S2003}
-----------------------------------------

The slide was incubated in 0.3% hydrogen peroxide for 30 mins to block endogenous peroxidase activity. Tissues were permeabilized with 0.5% Triton X-100 for 30 mins and incubated with working strength citrate buffer (pH 6.0) for 15 mins to retrieve the antigen of interest. After three washes in PBS, the slides were blocked in 5% normal goat serum. Samples were then cross-reacted with anti-METTL3 antibody (Abcam, ab195352; Cambridge, UK) that was diluted 1:100 and incubated with the sample for 2 hrs at room temperature. A secondary horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (H+L) was incubated with the slides for 30 mins. In addition, nuclei were counterstained with DAPI. Stained sections were visualized using a Leica fluorescence microscope.

Cell monolayers were lysed by incubating with RIPA buffer (Beyotime, Shanghai, People\'s Republic of China) that was supplemented with a protease inhibitor cocktail (Sigma) on ice for 30 mins. Lysates were centrifuged at 12,000 *g* for 20 mins, and supernatants were harvested and saved. The protein concentrations were determined using a BCA Protein Assay Kit (Boster, Pleasanton, CA, USA). Proteins were separated by SDS-PAGE using an 8--10% PAGEand transferred to nitrocellulose membranes (BioRad, Hercules, CA, USA).

The membranes were then blocked by 5% milk for 1 hr at room temperature. After four washes in PBST (PBS supplemented with 0.5% Triton X-100), membranes were immunoblotted with HRP-conjugated goat anti-mouse antibody (1:10,000) for 1 hr. The signal strength of revealed protein bands was detected with an enhanced chemiluminescence (ECL) substrate and captured with Image-Lab software (BioRad). Rabbit monoclonal antibody METTL3, P38, p-P38, ERK, p-ERK, JNK, and p-JNK were purchased from Cell Signaling Technology, Inc. (St. Louis, MO, USA). Detection of the relative protein band intensities of GAPDH served as an internal loading control.

Proliferation and colony formation assay {#S0002-S2004}
----------------------------------------

Approximately 5×10^3^ cells were seeded into 96-well flat-bottomed plates, and the real-time proliferation of those seeded cells was detected by the IncuCyte® S3 Live Cell Analysis System (Roche Applied Sciences, Indianapolis, IN, USA). Cell growth was assessed for 4 days.

For the colony formation assay, 5--1,000 cells were seeded into 6-well culture plates and cultured for 14 days. Four percent paraformaldehyde was used to fix cells for 10 mins and crystal violet aqueous solution was used to stain cells (Beyotime) for 15 mins. The plates were photographed, and the colonies were then counted. All experiments were independently set up three times, and the representative results of this assay are shown.

Transwell migration and invasion assays {#S0002-S2005}
---------------------------------------

For the migration assays, approximately 4×10^4^ cells were suspended in 200 μL serum-free RPMI-1640 and added into the upper chamber of a Transwell plate (Corning, New York, NY, USA) with an 8 μm pore size polycarbonate filter. The lower chamber had 500 μL complete culture medium with 10% FBS dispensed. The cells were cultured for 48 hrs, following which cells were fixed in 4% paraformaldehyde and then stained with crystal violate. A cotton swab was used to remove cells on the upper surface of the filter manually. The migrating cells were observed by microscopy, and the average value of the crystal violate intensity was calculated. The invasion assay was performed similarly for a migration assay with the exception of dispensing 5% Matrigel into the upper chamber before seeding cells into the culture system.

RNA isolation and quantitative real-time PCR assays {#S0002-S2006}
---------------------------------------------------

Total RNA was separated from cultured cells with TRIzol reagent (Invitrogen, Carlsbad, CA, USA). RT-PCR used a commercially available Reverse Transcription Kit (Toyobo, Osaka, Japan). qPCR assays were performed by the SYBR Green kit (Toyobo) on the ABI7300 instrument. The assay was performed across three biological replicates.

Statistical analysis {#S0002-S2007}
--------------------

An optimized cutoff of METTL3 expression was generated using R (maxstat package; Torsten Hothorn; <https://cran.r-project.org/web/packages/maxstat/index.html>). Survival curves were calculated using a Kaplan--Meier method and statistically significant differences were determined by a log-rank test. Data were analyzed with GraphPad Prism 5 (GraphPad Software Inc, San Diego, CA, USA) and presented as the mean ± SD about the mean. An unpaired two-sided Student's *t*-test was used to analyze differences of multiple experimental groups. Alpha values at *P*\<0.05 were considered statistically significant. We obtained CRC expression profiles from the National Center for Biotechnology Information Gene Expression Omnibus database (accession codes GSE33113 and GSE39582) and analyzed these expression profiles using gene set enrichment analysis (GSEA; Subramanian et al, 2005).

Results {#S0003}
=======

Correlation between the METTL3 expression and clinical features in CRC patients {#S0003-S2001}
-------------------------------------------------------------------------------

Immunohistochemistry of METTL3 was conducted in a tissue microarray ([Figure 1](#F0001){ref-type="fig"}). 181 patients were enrolled with comprehensive baseline clinical characteristics. 181 CRC patients were divided into METTL3 expression group (n=47) and no METTL3 expression group (n=134). The clinical features of both groups were compared ([Table 1](#T0002){ref-type="table"}), which indicated that the negative expression of METTL3 was significantly correlated with larger tumor size (*P*=0.031) and higher metastasis rates (*P*=0.002).Table 1Relationship between methyltransferase 3 (METTL3) expression and the clinicopathological characteristics of the studied patient groupsVariableTotalMETTL3*P* valueNegative (n=134)Positive (n=47)Age0.662 \<605741 (71.9)16 (28.1) ≥6012493 (75.0)31 (25.0)Gender0.949 Male9772 (74.2)25 (25.8) Female8462 (73.8)22 (26.2)Tumor size**0.031** ≤159161 (67.0)30 (33.0) \>159073 (81.1)17 (18.9)Metastasis**0.002** Tumor metastasis70 (0.0)7 (100.0) No metastasis174134 (77.0)40 (23.0)Histological grade0.601 I--II158118 (74.7)40 (25.3) III--IV2316 (69.6)7 (30.4)Tumor stage0.734 T1--T21712 (70.6)5 (29.4) T3--T4164122 (74.3)42 (25.6)[^2] Figure 1Differential expression of methyltransferase 3 (METTL3) in microarray. (**A**) Negative expression of METTL3. (**B**) Weak expression of METTL3. (**C**) Strong expression of METTL3. The positive expression of METTL3 is indicated by red arrows.

Expression of METTL3 is positively correlated with better survival in CRC patients {#S0003-S2002}
----------------------------------------------------------------------------------

To further determine the clinical relevance, we assessed the correlation between METTL3 expression and prognosis in CRC patients. Univariate analysis ([Figure 2A](#F0002){ref-type="fig"}) indicated that high METTL3 expression was correlated with longer survival time (*P*=0.011). Analysis of GEO survival data also suggested that CRC patients with high METTL3 expression had lower disease-free survival rates ([Figure 2B](#F0002){ref-type="fig"} and [C](#F0002){ref-type="fig"}). In addition, tumor size (*P*=0.006), metastasis (*P*=0.002), clinical stage (*P*=0.0001) and tumor classification (*P*=0.025) were associated with survival by univariate analysis. Moreover, multivariate analysis indicated that tumor location, tumor size, clinical stage, tumor classification and METTL3 expression status were independent prognostic factors ([Table 2](#T0003){ref-type="table"}).Table 2Multivariate analysis of overall survival in 181 CRC patientsVariableHRUnivariate analysis*P*HRMultivariate analysis*P*95% CI95% CIAge ≥60 vs. \<601.1850.756--1.8560.459Gender Male vs. female1.0360.681--1.5770.867Tumor side Right vs. left0.8980.587--1.3730.6190.5990.378--0.948**0.029**Tumor size \>15 vs. \<151.8171.187--2.781**0.006**1.7441.121--2.713**0.014**Metastasis Yes vs. no3.4921.591--7.665**0.002**Clinical stage III--IV vs. I--II2.9771.781--4.978**0.000**2.8361.661--4.842**0.000**Tumor stage T2--T4 vs. T13.7211.176--11.774**0.025**3.3151.039--10.575**0.043**METTL3 expression Negative vs. positive2.0241.106--3.529**0.013**1.9081.087--3.347**0.024**[^3][^4] Figure 2Correlation between expression of METTL3 and survival. (**A**) Expression of METTL3 is positively correlated with better survival in CRC patients (log-rank test, *P*=0.011). (**B**) Kaplan--Meier survival curves show that patients with high METTL3 expression had reduced disease-free survival time compared with patients with low expression of METTL3 (log-rank test, *P*=0.018; GSE33113: High METTL3=13; Low METTL3=75; time=months). (**C**) Patients with high METTL3 expression were associated with poor disease-free survival (log-rank test, *P*=0.03; GSE39582: high METTL3=371; low METTL3=186; time=months).**Abbreviations:**CRC, colorectal cancer; METTL3, methyltransferase 3.

Knockdown of METTL3 promotes proliferation and metastasis in CRC cells {#S0003-S2003}
----------------------------------------------------------------------

We established a stable METTL3 knockdown models in HCT16 and DLD1 cells with two shRNA (shMETTL3-1 and shMETTL3-2) to investigate the function of METTL3 in CRC cells. Successful knockdown of METTL3 was validated by qRT-PCR and western blot ([Figure 3A](#F0003){ref-type="fig"} and B). Knockdown of METTL3 obviously promoted CRC cell proliferation ([Figure 3C](#F0003){ref-type="fig"}) and the number of colony formation ([Figure 3D](#F0003){ref-type="fig"}). The result of transwell cell migration assay suggested that knockdown of METTL3 significantly increased the migration and invasion abilities of CRC cell ([Figure 3E](#F0003){ref-type="fig"} and [F](#F0003){ref-type="fig"}). Our results suggest that METTL3 may inhibit CRC cellular growth and metastasis.Figure 3Knockdown of METTL3 promoted CRC proliferation and migration. (**A**) Downregulation of METTL3 in HCT116 and DLD1 cell lines was validated with qRT-PCR (\**P*\<0.05). (**B**) Knockdown of METTL3 in HCT116 and DLD1 cell lines was validated by Western blot assay (\**P*\<0.05). (**C**) Downregulation of METTL3 significantly promoted CRC cellular proliferation. (**D**) Downregulation of METTL3 clearly increased the number of colony formation. (**E**) Downregulation of METTL3 promoted cell migration capacity. (F) Knockdown of METTL3 enhanced cellular invasion ability. \**P*\<0.05. All experiments were independently set up three times.**Abbreviations:**CRC, colorectal cancer; METTL3, methyltransferase 3.

Overexpression of METTL3 inhibited CRC cellular growth and metastasis {#S0003-S2004}
---------------------------------------------------------------------

We then overexpressed METTL3 in HCT8 and KM12 cell lines. Overexpression of METTL3 was demonstrated in both qRT-PCR and western blot analyses ([Figure 4A](#F0004){ref-type="fig"} and [B](#F0004){ref-type="fig"}). METTL3 overexpression remarkably inhibited CRC cell proliferation and colony formation efficiency ([Figure 4C](#F0004){ref-type="fig"} and [D](#F0004){ref-type="fig"}). Furthermore, overexpression of METTL3 significantly inhibited CRC cellular migration and invasion abilities ([Figure 4E](#F0004){ref-type="fig"} and [F](#F0004){ref-type="fig"}). Results from knockdown and overexpression models indicated that METTL3 might serve as a suppressor gene that inhibits CRC cellular proliferation and metastasis.Figure 4Overexpression of METTL3 inhibited CRC growth and migration. (**A**) Overexpression of METTL3 in KM12 and HCT8 cells was validated by qRT-PCR (\**P*\<0.05). (**B**) Overexpression of METTL3 in KM12 and HCT8 cells was validated by Western blot assay (\**P*\<0.05). (**C**) Overexpression of METTL3 inhibited cellular proliferation. (**D**) Overexpression of METTL3 was clearly associated with decreased number of colony formation. (**E**) Overexpression of METTL3 inhibited cell migration capacity. (**F**) Overexpression of METTL3 inhibited cell invasion capacity. \**P*\<0.05. All experiments were independently set up three times.**Abbreviations:** CRC, colorectal cancer; METTL3, methyltransferase 3.

METTL3 inhibited CRC cell proliferation and migration by modulating the p38/ERK pathways {#S0003-S2005}
----------------------------------------------------------------------------------------

We further investigated the role of METTL3 in the MAPK signaling pathway. The results demonstrated that p-p38 and p-ERK expression was significantly higher in the METTL3 knockdown models, while lower in the METTL3 overexpression groups. However, the expression of both p-JNK and JNK was unchanged when comparing both groups ([Figure 5A](#F0005){ref-type="fig"}). Thus, we tested whether METTL3 affects cell proliferation through the P38 or ERK pathways. In these studies, small-molecule inhibitors of p38 kinase or ERK kinases were, respectively, used to assess the effects of these inhibitors on migration and proliferation ([Figure 5B](#F0005){ref-type="fig"} and [C](#F0005){ref-type="fig"}). Compared with the control group, the inhibitors of p38 or ERK kinases significantly inhibited the migration, invasion and proliferation abilities that were induced by knockdown of METTL3. Furthermore, we found that the effects of these inhibitors on migration, invasion and proliferation had no significant difference compared with DMSO in HCT116 shNC group ([Figure S1A](#SF0001) and [B](#SF0001)). These findings suggested that METTL3 might play a role in inhibiting CRC cell proliferation and migration by modulating the p38/ERK pathways.Figure 5Changes in the p38/ERK pathways. (**A**) Knockdown of METTL3 resulted in changes in the expression of p38/ERK markers with a gain in p-p38 and p-ERK. By contrast, overexpression of METTL3 promoted losses in p-p38 and p-ERK. \**P*\<0.05. (**B**) Migration and cellular invasion capacities following METTL3 knockdown could be rescued by using inhibitors of p38 kinase or ERK kinases. (**C**) Proliferation capacities following METTL3 knockdown could be rescued by using inhibitors of p38 kinase or ERK kinases. All experiments were independently set up three times.**Abbreviation:**METTL3, methyltransferase 3.Figure S1The effects of p38 and ERK kinases inhibitors on migration, invasion and proliferation. (**A**) The effects of these inhibitors on migration and invasion had no significant difference compared with DMSO in HCT116 shNC group. (**B**) The effects of these inhibitors on proliferation had no significant difference compared with DMSO in HCT116 shNC group. All experiments were independently set up three times.**Abbreviation: **DMSO, Dimethyl sulfoxide.

Discussion {#S0004}
==========

Even though many biological processes are involved in the modification of m^6^A, its specific role in CRC remains largely obscure. The methyltransferase METTL3 has been reported to participate in tumorigenesis and the development of many cancers.[@CIT0016],[@CIT0017] However, relatively few studies have reported the functional role of METTL3 in CRC carcinogenesis and development.

The present study showed that loss of METTL3 expression was correlated with a larger tumor size, an advanced stage of development and metastatic disease in CRC. Furthermore, positive METTL3 expression was shown to be an independent and favorable prognostic factor in CRC, suggesting that METTL3 expression might affect CRC prognosis. Accordingly, METTL3 can affect CRC cellular functions including proliferation, migration and invasion. More importantly, we identified both p38 and ERK as downstream targets of METTL3. Thus, our findings shed new light on the progression of CRC development.

Our study had indicated that METTL3 acted as a tumor-suppressor gene in CRC, which was consistent with carcinostasis role in renal cancer cell.[@CIT0016] However, Chen et al[@CIT0015] reported that when METTL3 serves as an oncogene, its functional expression could contribute to the progression of hepatocellular cancer development. In their study, it was shown that dysregulation of METTL3 silenced the function of the tumor-suppressor SOCS2 and promoted liver carcinogenesis.[@CIT0015] Moreover, METTL3 can promote breast cancer disease progression by inhibiting the tumor-suppressor let-7g.[@CIT0017] Additionally, METTL3 was also reported to promote bladder cancer progression via AFF4/NF-κB/MYC signaling network.[@CIT0018] The main reason for the dual role of METTL3 in the regulation of cancer might account for the differences in the targeted pathways and cancer heterogeneity.

Functionally, we investigated the potential molecular mechanisms by which METTL3 affects CRC cell proliferation through regulating p38/ERK signaling pathway. It has been reported that the p38/ERK signaling pathway has long been known to be essential in cell proliferation and metastasis in different cancer types.[@CIT0019]--[@CIT0021] In this study, p-P38 and p-ERK were activated in the METTL3 knockdown group. Whereas, the expression levels of p-P38 and p-ERK were lower in METTL3 overexpression group. Moreover, blocking p38 and ERK kinase can inhibit the migration and invasion that was induced by knockdown of METTL3. Therefore, this study provided evidence that METTL3 might affect progression in CRC through the p38/ERK signaling pathway. However, it remains unclear whether m^6^A modification was regulated and which target was modulated. Therefore, further experiments are needed to clarify this fundamental question.

In summary, the present study has implicated METTL3 as a favorable prognostic factor in CRC patients. In addition, METTL3 regulated the cellular proliferation, migration and invasion capabilities in CRC and discovered that the p38/ERK pathways were involved in the molecular mechanisms of these observed functional behaviors in CRC. Thus, our finding may provide new insights into the role of tumor-suppressor and molecular mechanism of METTL3 by p38/ERK pathways in CRC.
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Table S1Two oligos for sh-methyltransferase (METTL3) lentivirus constructNoStartOli oligo sequence go typeSh-M3-1Top strand5'-CCGGCTCAGTGGATCTGTTGTGATACTCGAGTATCACAACAGATCCAC\
TGAGTTTTTG-3'Bottom strand5'- AATTCAAAAACTCAGTGGATCTGTTGTGATAGAGCTCTATCACAACAG\
ATCCACTGAG-3'Sh-M3-2Top strand5'-CCGGCAGGAGATCCTAGAGCTATTACTCGAGTAATAGCTCTAGGATCT\
CCTGTTTTTG-3'Bottom strand5'-AATTCAAAAACAGGAGATCCTAGAGCTATTAGAGCTCTAATAGCTCTA\
GGATCTCCTG-3'[^5]

[^1]: These authors contributed equally to this work

[^2]: **Notes:** Bold: *P*\<0.05, *P* values were two-tailed and based on Pearson Chi-square test.

[^3]: **Notes:** Bold: *P*\<0.05, *P* values were two-tailed and based on Pearson Chi-square test.

[^4]: **Abbreviations:**CRC, colorectal cancer; METTL3, methyltransferase 3.

[^5]: **Abbreviations:** Sh-M3-1, shMETTL3-1; Sh-M3-2, shMETTL3-2.
